Drugs / NGM120
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03392116 | Jan 2018 → Jan 2019 | — | NGM Biopharmaceuticals, Inc | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04068896 | Oct 2019 → Sep 2023 | colorectal cancer, esophageal cancer, gastric cancer, head and neck squamous cell carcinoma +6 | NGM Biopharmaceuticals, Inc | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07033026 | Jun 2025 → Apr 2027 expected | colorectal cancer | NGM Biopharmaceuticals, Inc | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2022-09-13 | NGM Biopharmaceuticals, Inc | Results NGM Bio Presents Updated Preliminary Findings from the Ongoing Phase 1b Dose Escalation Trial of NGM120 in Combination with Gemcitabine and Nab-paclitaxel in Patients with Metastatic Pancreatic Cancer at AACR Special Conference: Pancreatic Cancer ngmbio.com ↗
These results demonstrate that treatment with the drug was well tolerated to date in the study with no dose-limiting toxicities and provided encouraging signals of anti-cancer activity in patients with metastatic pancreatic cancer. |
| 2022-09-06 | NGM Biopharmaceuticals, Inc | Results NGM Bio Presents Updated Preliminary Findings for a Subgroup of Patients with Advanced Prostate Cancer from the Ongoing Phase 1a Dose Escalation Trial of NGM120 in Patients with Advanced Solid Tumors at the ESMO Annual Congress ngmbio.com ↗
These results demonstrate that treatment with NGM120 was well tolerated to date in the study with no dose-limiting toxicities and provide encouraging signals of anti-cancer activity in patients with advanced prostate cancer. |
| 2021-09-16 | NGM Biopharmaceuticals, Inc | Results NGM Bio Presents Preliminary Findings from Ongoing Phase 1a/1b Dose Escalation Study of NGM120 in Patients with Advanced Solid Tumors at the ESMO Virtual Congress 2021 ngmbio.com ↗
These preliminary results demonstrated that treatment with the drug was well tolerated to date in the study with no dose-limiting toxicities and provided encouraging initial signals of anti-cancer activity in patients with metastatic pancreatic cancer. |
All press releases naming this drug 7 releases
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NGM120 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07033026 ↗ |
| Action | Inhibit | “GFRAL Antagonist” NCT04068896 ↗ |
| Modality | Monoclonal antibody | “NGM120, a GFRAL Antagonist Monoclonal Antibody Blocking GDF15 Signaling” NCT04068896 ↗ |
| Route | Subcutaneous | “Subcutaneous Injection” NCT03392116 ↗ |
| Target | GFRAL | “GFRAL Antagonist” NCT04068896 ↗ |